RxE2

RxE2 Overview

RxE2 Inc specializes in decentralized clinical trials by integrating pharmacy practice into all aspects of the trial process. This approach allows local pharmacists to leverage their patient insights to enhance accessibility for participants, streamline trial operations, and reduce costs. By involving pharmacists as medication experts, RxE2 aims to provide more accurate data for study sponsors and improve the overall efficiency of clinical trials. in 2021, RxE2 established a local R&D center following the acquisition of Habitu, which integrated the activity of the Start-Up into the global company.

Latest News

Jan 11, 2021 · www.prnewswire.com

growth-positive

RxE2 Agrees to Acquire Habitu to Form the First AI Driven, Pharmacist-Led, Clinical Trial Platform

RxE2 has agreed to acquire Habitu, an Israeli-based technology company that focuses on peoples habits and behaviors to create an AI-powered engine for analyzing patient data in clinical trials. The acquisition will enhance RxE2s pharmacist-led trial services and improve patient outcomes. Habitus technology platform will enable RxE2 to provide and manage pharmacist-led trial services in a distributed model, localizing the decentralized clinical trial model. The AI-powered engine can predict potential challenges and improve decision-making for pharmacists and medical teams. RxE2 aims to make decentralized clinical trials more accessible, reduce timelines and costs, and provide more accurate data.

Acquisition

Team Members

1

Employees: 1-10

Web & Social Links

Locations

Hod Hasharon, Israel

Fargo, ND, USA

Photos & Videos

No files yet

RxE2 Internal

Recent Updates

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info